Nemera Receives Drug Manufacturing Authorization for its Autoinjector Facility

News
Article

Nemera is now authorized to handle, assemble, sterilize, and store pharmaceutical drugs and medicinal products for autoinjector combination products at its facility in Neuenburg, Germany.

Nemera received a Pharmaceutical Drug Manufacturing Authorization from the German Government Drug Administration according to the German Drug and Medicinal Product Law for its Neuenburg manufacturing facility in Germany on Sept. 4, the company announced in a Sept. 27, 2017 press release. The certification gives the manufacturing plant the approval to handle, assemble, sterilize, and store pharmaceutical drugs and medicinal products for autoinjectors.

This approval confirms that Nemera meets the highest standards required to ensure the manufacturing and testing of the above-mentioned drug, as well as medicinal and medical products. The pharmaceutical drug manufacturing certification is a required regulatory step to allow Nemera to provide a complete set of services and additional support for the development and manufacturing of pharmaceutical combination products and drug delivery devices.

Nemera currently markets devices in more than 40 countries and operates four facilities in Europe and the United States. Nemera’s services and products include several delivery routes: parenteral (autoinjectors, pens, safety devices, and implanters), ophthalmic (multidose, preservative-free eyedroppers), nasal, buccal, auricular (pumps, valves and actuators for sprays), inhalation (pressurized metered dose inhalers and dry powder inhalers), dermal, and transdermal (airless and atmospheric dispensers).

Source: Nemera

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content